Background: Spring birth has been found to be associated with increase in the risk of MS. However, this effect is reportedly found particularly in HLA-DR15 positive patients.
Objective: Examine the month of birth (MOB) effect in Finnish MS patients and its association with HLA-DR15.
Methods: Using the national register on hospitalizations during 1979–2004 we identified 8359 MS patients. We used a χ2-analysis to compare the distribution of MOB in MS patients versus age-adjusted controls. Patients were subdivided into 10-year birth cohorts to analyse temporal variations in MOB. A subgroup of HLA-typed MS patients (n = 657) and a population sample of healthy donors from the Finnish Bone Marrow Donor Registry (n = 19,805) were included to analyse connections between HLA-DR15 and MOB.
Results: An April birth was associated with a 9.4% increased risk of MS (p = 0.008), whereas November birth was associated with an 11.1% decreased risk (p = 0.004) compared with the expected birth distribution. No temporal clustering in the MOB effect was found during 1900–1988. Both HLA-DR15 positive (34% increase, p = 0.043) and DR15 negative (48% increase, p = 0.0095) MS patients exhibited an increase in spring births (in May). HLA-DR15 in healthy subjects was not associated with MOB.
Conclusions: We confirm that spring birth increases MS risk. This phenomenon was not associated with HLA-DR15 and there was no evidence of temporal clustering. The MOB effect suggests that early developmental processes may modulate MS risk.
TemplerDITrentNHSpencerDA. Season of birth in multiple sclerosis. Acta Neurol Scand1992; 85: 107–109.
2.
WillerCJDymentDASadovnickADRothwellPMMurrayTJEbersGC; Canadian Collaborative Study Group. Timing of birth and risk of multiple sclerosis: population based study. BMJ2005; 330: 120.
3.
BayesHKWeirCJO’LearyC. Timing of birth and risk of multiple sclerosis in the Scottish population. Eur Neurol2009; 63: 36–40.
4.
StaplesJPonsonbyALLimL. Low maternal exposure to ultraviolet radiation in pregnancy, MOB, and risk of multiple sclerosis in offspring: longitudinal analysis. BMJ2010; 340: c1640.
5.
SadovnickADDuquettePHerreraB. A timing-of-birth effect on multiple sclerosis clinical phenotype. Neurology2007; 69: 60–62.
6.
RamagopalanSVLinkJByrnesJK. HLA-DRB1 and month of birth in multiple sclerosis. Neurology2009; 73: 2107–2111.
7.
HandunnetthiLRamagopalanSVEbersGC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology2010; 74: 1905–1910.
8.
OlerupOHillertJ. HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. Tissue Antigens1991; 38: 1–15.
9.
LincolnMRMontpetitACaderMZ. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet2005; 37: 1108–1112.
10.
RamagopalanSVMaugeriNJHandunnetthiL. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet2009; 5: e1000369.
11.
ChabasDTaheriSRenierCMignotE. The genetics of narcolepsy. Annu Rev Genomics Hum Genet2003; 4: 459–483.
12.
DauvilliersYCarlanderBMolinariN. Month of birth as a risk factor for narcolepsy. Sleep2003; 26: 663–665.
13.
SumelahtiMLTienariPJWikströmJ. Regional and temporal variation in multiple sclerosis incidence in Finland during 1979–93. Neuroepidemiology2000; 19: 67–75.
14.
SumelahtiMLTienariPJWikströmJ. Increasing prevalence of multiple sclerosis in Finland. Acta Neurol Scand2001; 103: 153–158.
15.
KokkonenJKoivistoMKirkinenP. Seasonal variation in serum-25-OH-D3 in mothers and newborn infants in northern Finland. Acta Paediatr Scand1983; 72: 93–96.
16.
Lamberg-AllardtCAla-HouhalaMAholaMParviainenMTRäsänenLVisakorpiJ. Vitamin D status of children and adolescents in Finland. Ann Nutr Metab1986; 30: 267–272.
17.
LaaksonenMPastinenTSjöroosM. HLA class II associated risk and protection against multiple sclerosis – a Finnish family study. J Neuroimmunol2002; 122: 140–145.
18.
BonettiAKoivistoKPirttiläT. A follow-up study of chromosome 19q13 in multiple sclerosis susceptibility. J Neuroimmunol2009; 208: 119–124.
19.
International Multiple Sclerosis Genetics Consortium, Wellcome Trust Case Control Consortium 2, SawcerS. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature2011; 476: 214–219.
20.
WestmanPKuisminTPartanenJKoskimiesS. An HLA-DR typing protocol using group-specific PCR-amplification followed by restriction enzyme digests. Eur J Immunogenet1993; 20: 103–109.
21.
SirénMKSarenevaHLokkiMLKoskimiesS. Unique HLA antigen frequencies in the Finnish population. Tissue Antigens1996, 48: 703–707.
22.
RamagopalanSVHegerABerlangaAJ. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res2010; 20: 1352–1360.
23.
RothwellPMStainesASmailP. Seasonality of birth of patients with childhood diabetes in Britain. BMJ1996; 312: 1456–1457.
24.
VaisermanAMCarstensenBVoitenkoVP. Seasonality of birth in children and young adults (0–29 years) with type 1 diabetes in Ukraine. Diabetologia2007; 50: 32–35.
25.
RothwellPMGutnikovSAMcKinneyPASchoberEIonescu-TirgovisteCNeuA. Seasonality of birth in children with diabetes in Europe: multicentre cohort study. BMJ1999; 319: 887–888.
26.
ÅkerblomHKVaaralaOHyötyH. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet2002; 115: 18–29.
27.
ThorsbyERønningenKS. Role of HLA genes in predisposition to develop insulin-dependent diabetes mellitus. Ann Med1992; 24: 523–531.
